Grant: Doctoral: Vanier Canada Graduate Scholarships
Université de Montréal
$150,000.00
Aberrant expression of the platelet aggregating cell surface protein podoplanin by acute promyelocytic leukemia blasts may explain the bleeding complications associated with this disease.
EF 2016-17
Résumé
Acute promyelocytic leukemia or APL represents 10% of newly diagnosed patients with acute myeloid leukemia. A portion of patients still die from the important bleedings that uniquely characterize this subgroup, and bleeding complications are more frequent and severe when diagnosis is delayed. The full understanding and early diagnosis of APL thus represent a clear unmet medical need. No specific therapy currently exists for this complication. I have recently identified a gene called podoplanin, which is uniquely expressed in APL and not in other forms of leukemias. Podoplanin has the capacity to bind and deplete blood platelets, which are essential components of blood clots. My hypothesis is that the abnormally high expression of podoplanin on the surface of APL cells leads to the depletion of circulating platelets in this disease and represents a key component of the bleeding manifestations specifically observed in these patients. To confirm our initial observations, we now propose to analyze podoplanin expression in a large collection of APL patients and in other leukemia samples, and verify its utility as a rapid and reliable diagnostic test. Moreover, we will determine if podoplanin expression levels predict the severity of bleeding in these patients (aim 1). We will also test the hypothesis that platelet aggregation (leading to their depletion from blood) is directly triggered by podoplanin expression on the surface of APL cells (aim 2). In aim 3, we will identify drugs that can modulate podoplanin expression in APL cells with the possibility of providing a solution for the bleeding disorder of such patients.
Programme
Doctoral: Vanier Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
362809
Name
Lavallée Vincent-Philippe
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Aberrant expression of the platelet aggregating cell surface protein podoplanin by acute promyelocytic leukemia blasts may explain the bleeding complications associated with this disease.
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Acute Promyelocytic Leukemia; Gene Expression; Genetics; Podoplanin; Primary Hemostasis
Abstract
Acute promyelocytic leukemia or APL represents 10% of newly diagnosed patients with acute myeloid leukemia. A portion of patients still die from the important bleedings that uniquely characterize this subgroup, and bleeding complications are more frequent and severe when diagnosis is delayed. The full understanding and early diagnosis of APL thus represent a clear unmet medical need. No specific therapy currently exists for this complication. I have recently identified a gene called podoplanin, which is uniquely expressed in APL and not in other forms of leukemias. Podoplanin has the capacity to bind and deplete blood platelets, which are essential components of blood clots. My hypothesis is that the abnormally high expression of podoplanin on the surface of APL cells leads to the depletion of circulating platelets in this disease and represents a key component of the bleeding manifestations specifically observed in these patients. To confirm our initial observations, we now propose to analyze podoplanin expression in a large collection of APL patients and in other leukemia samples, and verify its utility as a rapid and reliable diagnostic test. Moreover, we will determine if podoplanin expression levels predict the severity of bleeding in these patients (aim 1). We will also test the hypothesis that platelet aggregation (leading to their depletion from blood) is directly triggered by podoplanin expression on the surface of APL cells (aim 2). In aim 3, we will identify drugs that can modulate podoplanin expression in APL cells with the possibility of providing a solution for the bleeding disorder of such patients.
Competitiondate
201611
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Lavallée, Vincent-Philippe
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~